REAP

Cancer treatment faces a major problem: it ultimately stops working for many patients because the tumor becomes resistant. The cellular origin of relapse is often linked to drug tolerant persister (DTP) cells, which survive treatment and can remain for years. Because of their scarcity and heterogeneity, the detection of DTP cells remains a technological challenge of enormous clinical importance. The objective of REAP is to develop two next generation multimodal imaging systems to reveal DTPs. A triple modal two-photon laser scanning optical coherence photoacoustic microscopy system will be built for the in vitro characterization of cancer organoids. Additionally, a dual-modality optical coherence photoacoustic tomography system will be implemented to visualize tumors in vivo in a mouse model. To enable greatly increased sensitivity and specificity, a new type of contrast agent based on biofunctionalized nanoparticles with tailor-made optical properties will be fabricated to specifically label DTPs. For improved imaging performance, several further technological advancements are targeted. Photoacoustic excitation will be realized using innovative microchip lasers addressing the needs for high-energy pulses, high-repetition rate, and multi-wavelength emission. To achieve the required resolution, novel photoacoustic detectors based on integrated optical micro-ring resonator technology will be developed with the potential to completely replace conventional piezoelectric ultrasound transducers. Furthermore, image acquisition speed will be increased by an order of magnitude with the help of an innovative laser source based on photonic integrated circuits at 780 nm. Finally, real-time data handling will be explored along with deep learning-based automatic analysis algorithms. The combined innovation in laser sources, detector technology, nanoparticles, and deep learning-based algorithms will create radically new imaging solutions reaching numerous applications.

2021

2025